

1/10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of  
Manning, et al.

Serial No. 10/668,067

Filed: September 22, 2003

For METHOD OF TREATING OSTEOARTHRITIS WITH INDUCIBLE NITRIC OXIDE  
SYNTHASE INHIBITORS

)  
) Attorney Docket No. 3151/1  
)  
) Group Art Unit: Unknown  
)  
) Examiner: Unknown

September 1, 2004

Commissioner of Patents  
PO Box 1450  
Alexandria, VA 22313

SIR:

**INFORMATION DISCLOSURE STATEMENT**


In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith various documents cited on the attached Form PTO 1449. Applicants respectfully request that the Examiner consider and enter all the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

Respectfully submitted,

Philip B. Polster, II, Reg. No. 43,864  
Attorney for Applicants  
(314) 274-9094 (St. Louis)

Pharmacia Corporation  
Corporate Patent Department  
P.O. Box 1027  
Chesterfield, MO 63006



**CERTIFICATE OF MAILING BY FIRST CLASS MAIL**

Serial No. 10/668,067  
Filing Date: 09/22/2003  
Examiner: Unknown  
Group Art Unit: Unknown  
Docket No. 3151/1


Date of Deposit: September 1, 2004

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313


IDS Statement  
IDS Form 1449  
40 IDS References  
Post Card

Michelle Becker

(Typed or printed name of person mailing paper or fee)



(Signature of person mailing paper or fee)



Sheet 1 of 3

<b>FORM PTO-1449</b> U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.: 3151</b>	<b>APPLICATION NO.: 10/668,067</b>
	<b>INVENTOR: Manning, et al.</b>	
	<b>Filed: 9/22/2003</b>	<b>Group:</b>

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	1	5684008	11/4/97	Hallinan	31	41	11/9/94
	2	5629322	5/13/97	Guthikonda	31	47	6/6/95

**FOREIGN PATENT DOCUMENTS**

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	3	93/13055	7/8/93	PCT				

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>FORM PTO-1449</b> U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	ATTY. DOCKET NO.: 3151/1	APPLICATION NO.: 10/668,067
	INVENTOR: Manning, et al.	
	Filed: 9/22/2003	Group:

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial		
	4	N. McCartney-Francis, 1993, Suppression of Arthritis by an inhibitor of nitric oxide synthase, The Journal of experimental medicine.178: 749-754
	5	A.R. Amin, 1995, The expression and regulation of nitric oxide synthase in human osteoarthritis-affected chondrocytes: evidence for an inducible "neuronal-like" nitric oxide synthase. J. Exp. Med. 182:2097-2102
	6	Pelletier, J. P., J. Martel-Pelletier, and D.S. Howell. 1997. Etiopathogenesis of osteoarthritis. In Arthritis and Allied Conditions. A Textbook of Rheumatology. W. J. Koopman, editor, Williams & Wilkins, Baltimore. 1969-1984
	7	Dean, D. D. 1991. Proteinase-mediated cartilage degradation in osteoarthritis.[Review]. Semin. Arthritis Rheum. 20:2-11
	8	Dore, S., J. P. Pelletier, J. A. DiBattista, G. Tardif, P. Brazeau, and J. Martel-Pelletier. 1994. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulator. Possible role of IGF-1-Binding Proteins. Arthritis Rheum. 37:253-263
	9	Hickery, M. S., R. M. J. Palmer, I. G. Charles, S. Moncada, and M. T. Bayliss. 1994. The role of nitric oxide in IL-1 and TNF $\alpha$ -induced inhibition of proteoglycan synthesis in human articular cartilage. Trans Orthop Res Soc 19:77.(Abstr.)
	10	Taskiran, D., M. Stefanovic-Racic, H. Georgescu, and C. Evans. 1994. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem. Biophys. Res Commun. 200:142-148
	11	Jarvinen, T. A. H., T. Moilanen, T. L. N. Jarvinen, and E. Moilanen. 1995. Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage. Mediators of Inflammation 4:107-111
	12	Stadler, J., M. Stefanovic-Racic, T. R. Billiar, R.D. Curran, L. A. McIntyre, H. I. Georgescu, R. L. Simmons, and C.H. Evans. 1991. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J. Immunol. 147:3917-3920
	13	Palmer, R. M. J., M. S. Hickery, I. G. Charles, S. Moncada, and M.T. Bayliss. 1993. Induction of nitric oxide synthase in human chondrocytes. Biochem. Biophys. Res. Commun. 193:398-405
	14	I. G. Charles, R. M. Palmer, M. S. Hickery, M. T. Bayliss, A. P. Chubb, V. S. Hall, D. W. Moss and S. Moncada. 1993. Cloning, characterization and expression of a cDNA encoding and inducible nitric oxide synthase from the human chondrocyte. Proc. Natl. Acad. Sci. USA. 90:11419-11423
	15	Pelletier, J. P., F. Mineau, P. Ranger, G. Tardif, and J. Martel-Pelletier. 1996. The increased synthesis of inducible nitric oxide inhibits IL-1Ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage 4:77-84

16	I. B. McInnes, B. P. Leung, M. Field, X. Q. Wei, F. -P. Huang, R. D. Sturrock, A. Kinninmonth, J. Weidner, R. Mumford and F. Y. Leiw. 1996. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. <i>J. Exp. Med.</i> 184:1519-1524
17	Farrell, A. J., D. R. Blake, R. M. Palmer, and S. Moncada. 1992 Increased concentration of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. <i>Ann Rheum. Dis.</i> 51 :1219-1222
18	Sakuri, H., H. Kohsaka, M. Liu, H. Higashiyama, Y. Hirata, K. Kanno, I. Saito, and N. Miyasaka. 1995. Nitric Oxide production and inducible nitric oxide synthase expression in inflammatory arthritis. <i>J. Clin. Invest.</i> 96:2357-2363
19	Cannon, G. W., S. J. Openshaw, J. B. Hibbs, Jr., J. R. Hoidal, T. P. Huecksteadt, and M.M. Griffiths. 1996. Nitric oxide production during adjuvant-induced and collagen-induced arthritis. <i>Arthritis Rheum.</i> 39:1677-1684
20	Evans, C.H., M. Stefanovic-Racic, and J. Lancaster. 1995. Nitric oxide and its role in orthopaedic disease. <i>Clin Orthop</i> 312:275-294
21	Stefanovic-Racic, M., J. Stadler, and C. H. Evans. 1993. Nitric oxide and arthritis. <i>Arthritis Rheum.</i> 36:1036-1044
22	Murrell, G. G. C., D. Jang, and R. J. Williams. 1995. Nitric oxide activates metalloprotease enzymes in articular cartilage. <i>Biochem Biophys Res Commun</i> 206:15-21
23	Connor, J.R., P. T. Manning, S. L. Settle, W. M. Moore, G. M. Jerome, R. K. Webber, F. S. Tjoeng, and M. G. Currie. 1995. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. <i>Eur J Pharmacol</i> 273 :15-24
24	Stefanovic-Racic, M., K. Meyers, C. Meschter, J.W. Coffey, R. A. Hoffman, and C. H. Evans. 1994. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. <i>Arthritis Rheum.</i> 37:1062-1069
25	Stefanovic-Racic, M., K. Meyers, C. Meschter, J. W. Coffey, R. A. Hoffman, and C. H. Evans. 1995. Comparison of the nitric oxide synthase inhibitors methylarginine and aminoguanidine as prophylactic and therapeutic agents in rat adjuvant arthritis. <i>J. Rheumatol.</i> 22:1922-1928
26	Moore, W. M., R. K. Webber, G. M. Jerome, F. S. Tjoeng, T. P. Misko, and M. G. Currie. 1994. L-N6-(1 – Iminoethyl) lysine: a selective inhibitor of inducible nitric oxide synthase. <i>J Med Chem</i> 37:3886-3888
27	Maier, R., G. Bible, J. Rediske, and M. Lotz. 1994. Inducible nitric oxide synthase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. <i>Biochim. Biophys. Acta</i> 145:1208 (Abstr.)
28	Pelletier, J. P., J. A. DiBattista, J. P. Raynauld, S. Wilhelm, and J. Martel-Pelletier. 1995. The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1 and oncogene protein synthesis in experimental osteoarthritis. <i>Lab. Invest.</i> 72:578-586
29	Pelletier, J. P., F. Mineau, J. P. Raynauld, J. F. Jr. Woessner, Z. Gunja-Smith, and J. Martel-Pelletier. 1994. Intraarticular injections with methylprednisolone acetate reduce osteoarthritis lesions in Parallel with chondrocyte stromelysin synthesis in experimental osteoarthritis. <i>Arthritis Rheum.</i> 37:414-423
30	Fernandes, J. C., J. Martel-Pelletier, I. G. Otterness, A. Lopez-Anaya, F. Mineau, G. Tardif, and J. P. Pelletier. 1995. Effects of tenidap on canine experimental osteoarthritis: I. Morphologic and metalloprotease analysis. <i>Arthritis Rheum.</i> 38:1290-1303
31	Mankin, H. J., H. Dorfman, L. Lippiello, and A. Zarins. 1971. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritis human hips. II. Correlation of morphology with biochemical and metabolic data. <i>J. Bone Joint Surg. Am.</i> 53:523-537
32	Cawson, T. E. and A. J. Barrett. 1979. A rapid and reproducible assay for collagenase using [1 – 14C] acetylated collagen. <i>Anal. Biochem.</i> 99:340-345

	33	Chavira, R. Jr., T. J. Burnett and J. H. Hageman. 1984. Assaying proteinases with azocoll. Anal. Biochem. 136:446-450
	34	Brandt, K. D. 1994. Insights into the natural history of osteoarthritis provided by the cruciate-deficient dog. An animal model of osteoarthritis. [Review]. Ann. NY Acad. Sci. 732:199-205
	35	Caron, J. P., J. C. Fernandes, J. Martel-Pelletier, G. Tardif, F. Mineau, C. Geng, and J. P. Pelletier. 1996. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: suppression of collagenase-1 expression. Arthritis Rheum. 39:1535-1544
	36	Van Beuningen, H. M., P. M. Van der Kraan, O. J. Arntz, and W. B. van den Berg. 1994. Transforming growth factor-beta 1 stimulates articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab. Invest. 71:279-290
	37	Blanco, F. J., R. L. Ochs, H. Schwarz and M. Lotz. 1995. Chondrocyte apoptosis induced by nitric oxide. Am. J. Pathol. 146:75-85
	38	Beckman, J. S. and Koppenol. 1996. Nitric oxide, superoxide and peroxynitrite: the good, the bad, and the ugly. Am. J. Physiol. 271:C1424-C1437
	39	Salvemini, D., P. T. Manning, B. S. Zweifel, K. Siebert, J. Connor, M. G. Curri, P. Needleman, and J. L. Masferrer. 1995. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J. Clin. Invest. 96:301-308
	40	Salvemini, D., Z. -Q. Wang, P. S. Wyatt, D.M. Bourdon, M. H. Marino, P. T. Manning, and M. G. Currie. 1996. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 118:829-838

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

(Form PTO-1449)